J NUCL MED 润色咨询

JOURNAL OF NUCLEAR MEDICINE

出版年份:1960 年文章数:3429 投稿命中率: 开通期刊会员,数据随心看

出版周期:Monthly 自引率:11.1% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2095031, encodeId=d47b209503135, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:转化医学;新药;核素治疗<br>经验分享:8月29日投出,9月23日大修,10月5日修回,10月19日接收。一共投了4篇文章,仅有此篇被接收,审稿人对文章的研究方向十分了解,提的意见非常中肯,编辑也特别认真,正文和图表都要求的很严格。JNM和EJNMMI同为核医学领域的10+期刊,感觉以前基本同一水平,但是现在来看,JNM已经和EJNMMI拉开了一段差距。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=93625573977, createdName=我又不乱来, createdTime=Thu Oct 20 20:32:09 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093849, encodeId=53e31093849da, content=关键词筛选有什么要求?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093850, encodeId=1e88109385001, content=关键词最多不能超过多少个?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=575464, encodeId=a5e15e546444, content=有投稿经验吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Aug 28 00:00:00 CST 2019, time=2019-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544313, encodeId=903a544313e4, content=赚翻了!去年发表了一篇,今年就突破6分,亲们,你们也需要有这样的眼光哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=385, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=13805560183, createdTime=Sun Jul 16 19:04:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833281, encodeId=18fe8332818b, content=很好,速度挺快的。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bbd5414038, createdName=ms9001418248751590, createdTime=Mon Aug 22 11:31:03 CST 2016, time=2016-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=506923, encodeId=0c6e506923b4, content=上条消息中那篇,被接受!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Mon Oct 20 23:45:00 CST 2014, time=2014-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=505277, encodeId=f5475052e769, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:超牛的杂志!曾经7分多,2011年曾经投过,被拒,但是给出很好的修改意见,转投欧洲核医学,得中!今年再次投稿,1个月左右修回,给出6个问题的小修,因为其中一个审稿人要求我增加其他方面的数据,因为那些数据已经整理成另外的文章,所以被我委婉拒绝,很担心修完被拒!又过去1个月才接收,其中的等待让人捉急啊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Aug 13 01:08:00 CST 2014, time=2014-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=491600, encodeId=bb694916005a, content=投一下,试试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=356, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Nov 24 19:47:00 CST 2012, time=2012-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=819940, encodeId=f3ff8199409e, content=不收入核医学技术的文章,技术类可以投美国核医学技术。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a365414012, createdName=ms3246569487495878, createdTime=Sat Jun 09 21:47:00 CST 2012, time=2012-06-09, status=1, ipAttribution=)]
    2022-10-20 我又不乱来

    审稿速度:1.0 | 投稿命中率:25.0
    偏重的研究方向:转化医学;新药;核素治疗
    经验分享:8月29日投出,9月23日大修,10月5日修回,10月19日接收。一共投了4篇文章,仅有此篇被接收,审稿人对文章的研究方向十分了解,提的意见非常中肯,编辑也特别认真,正文和图表都要求的很严格。JNM和EJNMMI同为核医学领域的10+期刊,感觉以前基本同一水平,但是现在来看,JNM已经和EJNMMI拉开了一段差距。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2095031, encodeId=d47b209503135, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:转化医学;新药;核素治疗<br>经验分享:8月29日投出,9月23日大修,10月5日修回,10月19日接收。一共投了4篇文章,仅有此篇被接收,审稿人对文章的研究方向十分了解,提的意见非常中肯,编辑也特别认真,正文和图表都要求的很严格。JNM和EJNMMI同为核医学领域的10+期刊,感觉以前基本同一水平,但是现在来看,JNM已经和EJNMMI拉开了一段差距。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=93625573977, createdName=我又不乱来, createdTime=Thu Oct 20 20:32:09 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093849, encodeId=53e31093849da, content=关键词筛选有什么要求?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093850, encodeId=1e88109385001, content=关键词最多不能超过多少个?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=575464, encodeId=a5e15e546444, content=有投稿经验吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Aug 28 00:00:00 CST 2019, time=2019-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544313, encodeId=903a544313e4, content=赚翻了!去年发表了一篇,今年就突破6分,亲们,你们也需要有这样的眼光哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=385, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=13805560183, createdTime=Sun Jul 16 19:04:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833281, encodeId=18fe8332818b, content=很好,速度挺快的。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bbd5414038, createdName=ms9001418248751590, createdTime=Mon Aug 22 11:31:03 CST 2016, time=2016-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=506923, encodeId=0c6e506923b4, content=上条消息中那篇,被接受!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Mon Oct 20 23:45:00 CST 2014, time=2014-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=505277, encodeId=f5475052e769, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:超牛的杂志!曾经7分多,2011年曾经投过,被拒,但是给出很好的修改意见,转投欧洲核医学,得中!今年再次投稿,1个月左右修回,给出6个问题的小修,因为其中一个审稿人要求我增加其他方面的数据,因为那些数据已经整理成另外的文章,所以被我委婉拒绝,很担心修完被拒!又过去1个月才接收,其中的等待让人捉急啊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Aug 13 01:08:00 CST 2014, time=2014-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=491600, encodeId=bb694916005a, content=投一下,试试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=356, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Nov 24 19:47:00 CST 2012, time=2012-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=819940, encodeId=f3ff8199409e, content=不收入核医学技术的文章,技术类可以投美国核医学技术。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a365414012, createdName=ms3246569487495878, createdTime=Sat Jun 09 21:47:00 CST 2012, time=2012-06-09, status=1, ipAttribution=)]
    2021-12-29 ms6000000264964247

    关键词筛选有什么要求?

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2095031, encodeId=d47b209503135, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:转化医学;新药;核素治疗<br>经验分享:8月29日投出,9月23日大修,10月5日修回,10月19日接收。一共投了4篇文章,仅有此篇被接收,审稿人对文章的研究方向十分了解,提的意见非常中肯,编辑也特别认真,正文和图表都要求的很严格。JNM和EJNMMI同为核医学领域的10+期刊,感觉以前基本同一水平,但是现在来看,JNM已经和EJNMMI拉开了一段差距。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=93625573977, createdName=我又不乱来, createdTime=Thu Oct 20 20:32:09 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093849, encodeId=53e31093849da, content=关键词筛选有什么要求?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093850, encodeId=1e88109385001, content=关键词最多不能超过多少个?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=575464, encodeId=a5e15e546444, content=有投稿经验吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Aug 28 00:00:00 CST 2019, time=2019-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544313, encodeId=903a544313e4, content=赚翻了!去年发表了一篇,今年就突破6分,亲们,你们也需要有这样的眼光哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=385, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=13805560183, createdTime=Sun Jul 16 19:04:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833281, encodeId=18fe8332818b, content=很好,速度挺快的。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bbd5414038, createdName=ms9001418248751590, createdTime=Mon Aug 22 11:31:03 CST 2016, time=2016-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=506923, encodeId=0c6e506923b4, content=上条消息中那篇,被接受!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Mon Oct 20 23:45:00 CST 2014, time=2014-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=505277, encodeId=f5475052e769, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:超牛的杂志!曾经7分多,2011年曾经投过,被拒,但是给出很好的修改意见,转投欧洲核医学,得中!今年再次投稿,1个月左右修回,给出6个问题的小修,因为其中一个审稿人要求我增加其他方面的数据,因为那些数据已经整理成另外的文章,所以被我委婉拒绝,很担心修完被拒!又过去1个月才接收,其中的等待让人捉急啊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Aug 13 01:08:00 CST 2014, time=2014-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=491600, encodeId=bb694916005a, content=投一下,试试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=356, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Nov 24 19:47:00 CST 2012, time=2012-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=819940, encodeId=f3ff8199409e, content=不收入核医学技术的文章,技术类可以投美国核医学技术。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a365414012, createdName=ms3246569487495878, createdTime=Sat Jun 09 21:47:00 CST 2012, time=2012-06-09, status=1, ipAttribution=)]
    2021-12-27 Gym璨烨

    关键词最多不能超过多少个?

    1

    展开1条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2095031, encodeId=d47b209503135, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:转化医学;新药;核素治疗<br>经验分享:8月29日投出,9月23日大修,10月5日修回,10月19日接收。一共投了4篇文章,仅有此篇被接收,审稿人对文章的研究方向十分了解,提的意见非常中肯,编辑也特别认真,正文和图表都要求的很严格。JNM和EJNMMI同为核医学领域的10+期刊,感觉以前基本同一水平,但是现在来看,JNM已经和EJNMMI拉开了一段差距。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=93625573977, createdName=我又不乱来, createdTime=Thu Oct 20 20:32:09 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093849, encodeId=53e31093849da, content=关键词筛选有什么要求?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093850, encodeId=1e88109385001, content=关键词最多不能超过多少个?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=575464, encodeId=a5e15e546444, content=有投稿经验吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Aug 28 00:00:00 CST 2019, time=2019-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544313, encodeId=903a544313e4, content=赚翻了!去年发表了一篇,今年就突破6分,亲们,你们也需要有这样的眼光哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=385, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=13805560183, createdTime=Sun Jul 16 19:04:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833281, encodeId=18fe8332818b, content=很好,速度挺快的。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bbd5414038, createdName=ms9001418248751590, createdTime=Mon Aug 22 11:31:03 CST 2016, time=2016-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=506923, encodeId=0c6e506923b4, content=上条消息中那篇,被接受!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Mon Oct 20 23:45:00 CST 2014, time=2014-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=505277, encodeId=f5475052e769, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:超牛的杂志!曾经7分多,2011年曾经投过,被拒,但是给出很好的修改意见,转投欧洲核医学,得中!今年再次投稿,1个月左右修回,给出6个问题的小修,因为其中一个审稿人要求我增加其他方面的数据,因为那些数据已经整理成另外的文章,所以被我委婉拒绝,很担心修完被拒!又过去1个月才接收,其中的等待让人捉急啊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Aug 13 01:08:00 CST 2014, time=2014-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=491600, encodeId=bb694916005a, content=投一下,试试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=356, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Nov 24 19:47:00 CST 2012, time=2012-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=819940, encodeId=f3ff8199409e, content=不收入核医学技术的文章,技术类可以投美国核医学技术。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a365414012, createdName=ms3246569487495878, createdTime=Sat Jun 09 21:47:00 CST 2012, time=2012-06-09, status=1, ipAttribution=)]
    2019-08-28 tomsyu

    有投稿经验吗?

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2095031, encodeId=d47b209503135, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:转化医学;新药;核素治疗<br>经验分享:8月29日投出,9月23日大修,10月5日修回,10月19日接收。一共投了4篇文章,仅有此篇被接收,审稿人对文章的研究方向十分了解,提的意见非常中肯,编辑也特别认真,正文和图表都要求的很严格。JNM和EJNMMI同为核医学领域的10+期刊,感觉以前基本同一水平,但是现在来看,JNM已经和EJNMMI拉开了一段差距。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=93625573977, createdName=我又不乱来, createdTime=Thu Oct 20 20:32:09 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093849, encodeId=53e31093849da, content=关键词筛选有什么要求?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093850, encodeId=1e88109385001, content=关键词最多不能超过多少个?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=575464, encodeId=a5e15e546444, content=有投稿经验吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Aug 28 00:00:00 CST 2019, time=2019-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544313, encodeId=903a544313e4, content=赚翻了!去年发表了一篇,今年就突破6分,亲们,你们也需要有这样的眼光哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=385, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=13805560183, createdTime=Sun Jul 16 19:04:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833281, encodeId=18fe8332818b, content=很好,速度挺快的。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bbd5414038, createdName=ms9001418248751590, createdTime=Mon Aug 22 11:31:03 CST 2016, time=2016-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=506923, encodeId=0c6e506923b4, content=上条消息中那篇,被接受!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Mon Oct 20 23:45:00 CST 2014, time=2014-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=505277, encodeId=f5475052e769, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:超牛的杂志!曾经7分多,2011年曾经投过,被拒,但是给出很好的修改意见,转投欧洲核医学,得中!今年再次投稿,1个月左右修回,给出6个问题的小修,因为其中一个审稿人要求我增加其他方面的数据,因为那些数据已经整理成另外的文章,所以被我委婉拒绝,很担心修完被拒!又过去1个月才接收,其中的等待让人捉急啊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Aug 13 01:08:00 CST 2014, time=2014-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=491600, encodeId=bb694916005a, content=投一下,试试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=356, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Nov 24 19:47:00 CST 2012, time=2012-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=819940, encodeId=f3ff8199409e, content=不收入核医学技术的文章,技术类可以投美国核医学技术。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a365414012, createdName=ms3246569487495878, createdTime=Sat Jun 09 21:47:00 CST 2012, time=2012-06-09, status=1, ipAttribution=)]
    2017-07-16 13805560183

    赚翻了!去年发表了一篇,今年就突破6分,亲们,你们也需要有这样的眼光哦

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2095031, encodeId=d47b209503135, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:转化医学;新药;核素治疗<br>经验分享:8月29日投出,9月23日大修,10月5日修回,10月19日接收。一共投了4篇文章,仅有此篇被接收,审稿人对文章的研究方向十分了解,提的意见非常中肯,编辑也特别认真,正文和图表都要求的很严格。JNM和EJNMMI同为核医学领域的10+期刊,感觉以前基本同一水平,但是现在来看,JNM已经和EJNMMI拉开了一段差距。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=93625573977, createdName=我又不乱来, createdTime=Thu Oct 20 20:32:09 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093849, encodeId=53e31093849da, content=关键词筛选有什么要求?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093850, encodeId=1e88109385001, content=关键词最多不能超过多少个?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=575464, encodeId=a5e15e546444, content=有投稿经验吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Aug 28 00:00:00 CST 2019, time=2019-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544313, encodeId=903a544313e4, content=赚翻了!去年发表了一篇,今年就突破6分,亲们,你们也需要有这样的眼光哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=385, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=13805560183, createdTime=Sun Jul 16 19:04:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833281, encodeId=18fe8332818b, content=很好,速度挺快的。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bbd5414038, createdName=ms9001418248751590, createdTime=Mon Aug 22 11:31:03 CST 2016, time=2016-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=506923, encodeId=0c6e506923b4, content=上条消息中那篇,被接受!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Mon Oct 20 23:45:00 CST 2014, time=2014-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=505277, encodeId=f5475052e769, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:超牛的杂志!曾经7分多,2011年曾经投过,被拒,但是给出很好的修改意见,转投欧洲核医学,得中!今年再次投稿,1个月左右修回,给出6个问题的小修,因为其中一个审稿人要求我增加其他方面的数据,因为那些数据已经整理成另外的文章,所以被我委婉拒绝,很担心修完被拒!又过去1个月才接收,其中的等待让人捉急啊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Aug 13 01:08:00 CST 2014, time=2014-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=491600, encodeId=bb694916005a, content=投一下,试试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=356, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Nov 24 19:47:00 CST 2012, time=2012-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=819940, encodeId=f3ff8199409e, content=不收入核医学技术的文章,技术类可以投美国核医学技术。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a365414012, createdName=ms3246569487495878, createdTime=Sat Jun 09 21:47:00 CST 2012, time=2012-06-09, status=1, ipAttribution=)]
    2016-08-22 ms9001418248751590

    很好,速度挺快的。

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2095031, encodeId=d47b209503135, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:转化医学;新药;核素治疗<br>经验分享:8月29日投出,9月23日大修,10月5日修回,10月19日接收。一共投了4篇文章,仅有此篇被接收,审稿人对文章的研究方向十分了解,提的意见非常中肯,编辑也特别认真,正文和图表都要求的很严格。JNM和EJNMMI同为核医学领域的10+期刊,感觉以前基本同一水平,但是现在来看,JNM已经和EJNMMI拉开了一段差距。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=93625573977, createdName=我又不乱来, createdTime=Thu Oct 20 20:32:09 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093849, encodeId=53e31093849da, content=关键词筛选有什么要求?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093850, encodeId=1e88109385001, content=关键词最多不能超过多少个?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=575464, encodeId=a5e15e546444, content=有投稿经验吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Aug 28 00:00:00 CST 2019, time=2019-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544313, encodeId=903a544313e4, content=赚翻了!去年发表了一篇,今年就突破6分,亲们,你们也需要有这样的眼光哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=385, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=13805560183, createdTime=Sun Jul 16 19:04:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833281, encodeId=18fe8332818b, content=很好,速度挺快的。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bbd5414038, createdName=ms9001418248751590, createdTime=Mon Aug 22 11:31:03 CST 2016, time=2016-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=506923, encodeId=0c6e506923b4, content=上条消息中那篇,被接受!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Mon Oct 20 23:45:00 CST 2014, time=2014-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=505277, encodeId=f5475052e769, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:超牛的杂志!曾经7分多,2011年曾经投过,被拒,但是给出很好的修改意见,转投欧洲核医学,得中!今年再次投稿,1个月左右修回,给出6个问题的小修,因为其中一个审稿人要求我增加其他方面的数据,因为那些数据已经整理成另外的文章,所以被我委婉拒绝,很担心修完被拒!又过去1个月才接收,其中的等待让人捉急啊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Aug 13 01:08:00 CST 2014, time=2014-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=491600, encodeId=bb694916005a, content=投一下,试试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=356, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Nov 24 19:47:00 CST 2012, time=2012-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=819940, encodeId=f3ff8199409e, content=不收入核医学技术的文章,技术类可以投美国核医学技术。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a365414012, createdName=ms3246569487495878, createdTime=Sat Jun 09 21:47:00 CST 2012, time=2012-06-09, status=1, ipAttribution=)]
    2014-10-20 匿名用户

    上条消息中那篇,被接受!

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2095031, encodeId=d47b209503135, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:转化医学;新药;核素治疗<br>经验分享:8月29日投出,9月23日大修,10月5日修回,10月19日接收。一共投了4篇文章,仅有此篇被接收,审稿人对文章的研究方向十分了解,提的意见非常中肯,编辑也特别认真,正文和图表都要求的很严格。JNM和EJNMMI同为核医学领域的10+期刊,感觉以前基本同一水平,但是现在来看,JNM已经和EJNMMI拉开了一段差距。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=93625573977, createdName=我又不乱来, createdTime=Thu Oct 20 20:32:09 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093849, encodeId=53e31093849da, content=关键词筛选有什么要求?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093850, encodeId=1e88109385001, content=关键词最多不能超过多少个?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=575464, encodeId=a5e15e546444, content=有投稿经验吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Aug 28 00:00:00 CST 2019, time=2019-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544313, encodeId=903a544313e4, content=赚翻了!去年发表了一篇,今年就突破6分,亲们,你们也需要有这样的眼光哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=385, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=13805560183, createdTime=Sun Jul 16 19:04:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833281, encodeId=18fe8332818b, content=很好,速度挺快的。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bbd5414038, createdName=ms9001418248751590, createdTime=Mon Aug 22 11:31:03 CST 2016, time=2016-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=506923, encodeId=0c6e506923b4, content=上条消息中那篇,被接受!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Mon Oct 20 23:45:00 CST 2014, time=2014-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=505277, encodeId=f5475052e769, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:超牛的杂志!曾经7分多,2011年曾经投过,被拒,但是给出很好的修改意见,转投欧洲核医学,得中!今年再次投稿,1个月左右修回,给出6个问题的小修,因为其中一个审稿人要求我增加其他方面的数据,因为那些数据已经整理成另外的文章,所以被我委婉拒绝,很担心修完被拒!又过去1个月才接收,其中的等待让人捉急啊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Aug 13 01:08:00 CST 2014, time=2014-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=491600, encodeId=bb694916005a, content=投一下,试试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=356, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Nov 24 19:47:00 CST 2012, time=2012-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=819940, encodeId=f3ff8199409e, content=不收入核医学技术的文章,技术类可以投美国核医学技术。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a365414012, createdName=ms3246569487495878, createdTime=Sat Jun 09 21:47:00 CST 2012, time=2012-06-09, status=1, ipAttribution=)]
    2014-08-13 匿名用户

    审稿速度:2.0 | 投稿命中率:50.0
    经验分享:超牛的杂志!曾经7分多,2011年曾经投过,被拒,但是给出很好的修改意见,转投欧洲核医学,得中!今年再次投稿,1个月左右修回,给出6个问题的小修,因为其中一个审稿人要求我增加其他方面的数据,因为那些数据已经整理成另外的文章,所以被我委婉拒绝,很担心修完被拒!又过去1个月才接收,其中的等待让人捉急啊!

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2095031, encodeId=d47b209503135, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:转化医学;新药;核素治疗<br>经验分享:8月29日投出,9月23日大修,10月5日修回,10月19日接收。一共投了4篇文章,仅有此篇被接收,审稿人对文章的研究方向十分了解,提的意见非常中肯,编辑也特别认真,正文和图表都要求的很严格。JNM和EJNMMI同为核医学领域的10+期刊,感觉以前基本同一水平,但是现在来看,JNM已经和EJNMMI拉开了一段差距。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=93625573977, createdName=我又不乱来, createdTime=Thu Oct 20 20:32:09 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093849, encodeId=53e31093849da, content=关键词筛选有什么要求?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093850, encodeId=1e88109385001, content=关键词最多不能超过多少个?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=575464, encodeId=a5e15e546444, content=有投稿经验吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Aug 28 00:00:00 CST 2019, time=2019-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544313, encodeId=903a544313e4, content=赚翻了!去年发表了一篇,今年就突破6分,亲们,你们也需要有这样的眼光哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=385, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=13805560183, createdTime=Sun Jul 16 19:04:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833281, encodeId=18fe8332818b, content=很好,速度挺快的。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bbd5414038, createdName=ms9001418248751590, createdTime=Mon Aug 22 11:31:03 CST 2016, time=2016-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=506923, encodeId=0c6e506923b4, content=上条消息中那篇,被接受!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Mon Oct 20 23:45:00 CST 2014, time=2014-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=505277, encodeId=f5475052e769, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:超牛的杂志!曾经7分多,2011年曾经投过,被拒,但是给出很好的修改意见,转投欧洲核医学,得中!今年再次投稿,1个月左右修回,给出6个问题的小修,因为其中一个审稿人要求我增加其他方面的数据,因为那些数据已经整理成另外的文章,所以被我委婉拒绝,很担心修完被拒!又过去1个月才接收,其中的等待让人捉急啊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Aug 13 01:08:00 CST 2014, time=2014-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=491600, encodeId=bb694916005a, content=投一下,试试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=356, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Nov 24 19:47:00 CST 2012, time=2012-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=819940, encodeId=f3ff8199409e, content=不收入核医学技术的文章,技术类可以投美国核医学技术。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a365414012, createdName=ms3246569487495878, createdTime=Sat Jun 09 21:47:00 CST 2012, time=2012-06-09, status=1, ipAttribution=)]
    2012-11-24 匿名用户

    投一下,试试

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2095031, encodeId=d47b209503135, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:转化医学;新药;核素治疗<br>经验分享:8月29日投出,9月23日大修,10月5日修回,10月19日接收。一共投了4篇文章,仅有此篇被接收,审稿人对文章的研究方向十分了解,提的意见非常中肯,编辑也特别认真,正文和图表都要求的很严格。JNM和EJNMMI同为核医学领域的10+期刊,感觉以前基本同一水平,但是现在来看,JNM已经和EJNMMI拉开了一段差距。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=93625573977, createdName=我又不乱来, createdTime=Thu Oct 20 20:32:09 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093849, encodeId=53e31093849da, content=关键词筛选有什么要求?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093850, encodeId=1e88109385001, content=关键词最多不能超过多少个?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=575464, encodeId=a5e15e546444, content=有投稿经验吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Aug 28 00:00:00 CST 2019, time=2019-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544313, encodeId=903a544313e4, content=赚翻了!去年发表了一篇,今年就突破6分,亲们,你们也需要有这样的眼光哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=385, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=13805560183, createdTime=Sun Jul 16 19:04:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833281, encodeId=18fe8332818b, content=很好,速度挺快的。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bbd5414038, createdName=ms9001418248751590, createdTime=Mon Aug 22 11:31:03 CST 2016, time=2016-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=506923, encodeId=0c6e506923b4, content=上条消息中那篇,被接受!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Mon Oct 20 23:45:00 CST 2014, time=2014-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=505277, encodeId=f5475052e769, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:超牛的杂志!曾经7分多,2011年曾经投过,被拒,但是给出很好的修改意见,转投欧洲核医学,得中!今年再次投稿,1个月左右修回,给出6个问题的小修,因为其中一个审稿人要求我增加其他方面的数据,因为那些数据已经整理成另外的文章,所以被我委婉拒绝,很担心修完被拒!又过去1个月才接收,其中的等待让人捉急啊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Aug 13 01:08:00 CST 2014, time=2014-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=491600, encodeId=bb694916005a, content=投一下,试试, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=356, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Nov 24 19:47:00 CST 2012, time=2012-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=819940, encodeId=f3ff8199409e, content=不收入核医学技术的文章,技术类可以投美国核医学技术。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a365414012, createdName=ms3246569487495878, createdTime=Sat Jun 09 21:47:00 CST 2012, time=2012-06-09, status=1, ipAttribution=)]
    2012-06-09 ms3246569487495878

    不收入核医学技术的文章,技术类可以投美国核医学技术。

    0

共12条页码: 1/2页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分